Pursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health hereby renews the provisional consent to the sale, supply or use in New Zealand of the medicines set out in the Schedule hereto:

Schedule

Note: This consent is given subject to the following conditions:

• This product should only be prescribed to patients already taking this product who are known to be intolerant to all other levothyroxine containing products.
• This product may also be prescribed to patients already taking this product who are not known to be intolerant to all other levothyroxine containing products, but for whom changing to another levothyroxine containing product is not clinically appropriate.

Note: This renewed consent is valid for two years from 11 November 2022.

Note: This consent is given subject to the following conditions:

• This product should only be prescribed to patients already taking this product who are known to be intolerant to all other levothyroxine containing products.
• This product may also be prescribed to patients already taking this product who are not known to be intolerant to all other levothyroxine containing products, but for whom changing to another levothyroxine containing product is not clinically appropriate.

Note: This renewed consent is valid for two years from 11 November 2022.

Dated this 4th day of November 2022.

CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).